Health TrialsbyHealthPanel

Multiple Myeloma in Remission

2

Review clinical trials related to Multiple Myeloma in Remission. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Universal CAR-T Cells Targeting Multiple Myeloma

The aim of this study is to assess the feasibility, safety and efficacy of universal CAR T cells targeting multiple myeloma. Another goal of the study is to learn more about the persistence and function of the universal CAR T cells in the body.

Participants needed: 20
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Shenzhen Geno-Immune Medical InstituteUpdated: Aug 26, 2026Locations: 1
Eligibility criteria

Patients with confirmed multiple myeloma failed curative treatment options (incl... [+10]

Pregnant or lactating women [+6]

Read more
Status: Not yet recruiting

BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma

Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This Phase 2 study will establish the safety and efficacy profile of LMY-920.

Participants needed: 90
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Luminary TherapeuticsUpdated: Aug 18, 2026
Eligibility criteria

No evidence of CNS lymphoma. [+11]

ASCT within 6 weeks prior to informed consent. [+14]

Read more